Clinical Research Progress of BTK Inhibitors in the Treatment of Autoimmune Diseases

被引：0

作者：

Lin, Pei ^{[1
]}

Zhang, Dandan ^{[1
]}

Lin, Jun ^{[1
]}

机构：

[1] Jiangnan Univ, Sch Life Sci & Hlth Engn, Wuxi 214122, Peoples R China

来源：

CURRENT TOPICS IN MEDICINAL CHEMISTRY | 2023年 / 23卷 / 28期

关键词：

Bruton's tyrosine kinase; Autoimmune disease; B cell receptor; Inhibitors; Rheumatoid arthritis; Multiple sclerosis; Systemic lupus erythematosus; BRUTONS TYROSINE KINASE; X-LINKED AGAMMAGLOBULINEMIA; PIRTOBRUTINIB; TOXICITIES; ACTIVATION; MECHANISMS; EFFICACY;

D O I：

10.2174/0115680266264515230921052521

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Bruton tyrosine kinase (BTK) is an important protein of the tyrosine kinase family and plays a key role in signal transduction, proliferation, migration, and survival in B lymphocytes. The inhibition of BTK is a promising therapy for various autoimmune diseases (AD) involving abnormal B cell function, such as rheumatoid arthritis (RA), multiple sclerosis (MS), and systemic lupus erythematosus (SLE). This article briefly summarizes the role of BTK in the BCR signaling pathway, the development process of BTK inhibitors, and especially the latest progress of their clinical trials for the treatment of AD.

引用

页码：2609 / 2620

页数：12

共 83 条

[71] Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies [J].

Tam, Constantine S. ;

Dimopoulos, Meletios ;

Garcia-Sanz, Ramon ;

Trotman, Judith ;

Opat, Stephen ;

Roberts, Andrew W. ;

Owen, Roger ;

Song, Yuqin ;

Xu, Wei ;

Zhu, Jun ;

Li, Jianyong ;

Qiu, Lugui ;

D'Sa, Shirley ;

Jurczak, Wojciech ;

Cull, Gavin ;

Marlton, Paula ;

Gottlieb, David ;

Munoz, Javier ;

Phillips, Tycel ;

Du, Chenmu ;

Ji, Meng ;

Zhou, Lei ;

Guo, Haiyi ;

Zhu, Hongjie ;

Chan, Wai Y. ;

Cohen, Aileen ;

Novotny, William ;

Huang, Jane ;

Tedeschi, Alessandra .

BLOOD ADVANCES, 2022, 6 (04) :1296-1308

[72] Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL [J].

Tam, Constantine S. ;

Trotman, Judith ;

Opat, Stephen ;

Burger, Jan A. ;

Cull, Gavin ;

Gottlieb, David ;

Harrup, Rosemary ;

Johnston, Patrick B. ;

Marlton, Paula ;

Munoz, Javier ;

Seymour, John F. ;

Simpson, David ;

Tedeschi, Alessandra ;

Elstrom, Rebecca ;

Yu, Yiling ;

Tang, Zhiyu ;

Han, Lynn ;

Huang, Jane ;

Novotny, William ;

Wang, Lai ;

Roberts, Andrew W. .

BLOOD, 2019, 134 (11) :851-859

[73] COLOCALIZATION OF X-LINKED AGAMMAGLOBULINEMIA AND X-LINKED IMMUNODEFICIENCY GENES [J].

THOMAS, JD ;

SIDERAS, P ;

SMITH, CIE ;

VORECHOVSKY, I ;

CHAPMAN, V ;

PAUL, WE .

SCIENCE, 1993, 261 (5119) :355-358

[74] DEFICIENT EXPRESSION OF A B-CELL CYTOPLASMIC TYROSINE KINASE IN HUMAN X-LINKED AGAMMAGLOBULINEMIA [J].

TSUKADA, S ;

SAFFRAN, DC ;

RAWLINGS, DJ ;

PAROLINI, O ;

ALLEN, RC ;

KLISAK, I ;

SPARKES, RS ;

KUBAGAWA, H ;

MOHANDAS, T ;

QUAN, S ;

BELMONT, JW ;

COOPER, MD ;

CONLEY, ME ;

WITTE, ON .

CELL, 1993, 72 (02) :279-290

[75] Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease [J].

von Hundelshausen, Philipp ;

Siess, Wolfgang .

CANCERS, 2021, 13 (05) :1-33

[76] Phosphorylation of two regulatory tyrosine residues in the activation of Bruton's tyrosine kinase via alternative receptors [J].

Wahl, MI ;

Fluckiger, AC ;

Kato, RM ;

Park, H ;

Witte, ON ;

Rawlings, DJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (21) :11526-11533

[77] Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors [J].

Wang, Eric ;

Mi, Xiaoli ;

Thompson, Meghan C. ;

Montoya, Skye ;

Notti, Ryan Q. ;

Afaghani, Jumana ;

Durham, Benjamin H. ;

Penson, Alex ;

Witkowski, Matthew T. ;

Lu, Sydney X. ;

Bourcier, Jessie ;

Hogg, Simon J. ;

Erickson, Caroline ;

Cui, Dan ;

Cho, Hana ;

Singer, Michael ;

Totiger, Tulasigeri M. ;

Chaudhry, Sana ;

Geyer, Mark ;

Alencar, Alvaro ;

Linley, Adam J. ;

Palomba, M. Lia ;

Coombs, Catherine C. ;

Park, Jae H. ;

Zelenetz, Andrew ;

Roeker, Lindsey ;

Rosendahl, Mary ;

Tsai, Donald E. ;

Ebata, Kevin ;

Brandhuber, Barbara ;

Hyman, David M. ;

Aifantis, Iannis ;

Mato, Anthony ;

Taylor, Justin ;

Abdel-Wahab, Omar .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (08) :735-743

[78] Oral methotrexate at doses 15-25 mg/week is non-inferior to parenteral regarding efficacy and safety in the treatment of rheumatoid arthritis: a systematic review and meta-analysis [J].

Wang, Fang ;

Tang, Jingliang ;

Li, Zhe ;

Qi, Yanyan ;

Li, Ganpeng .

CLINICAL RHEUMATOLOGY, 2022, 41 (09) :2701-2712

[79] Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect [J].

Wang, Haoran ;

Guo, Hao ;

Yang, Jingyi ;

Liu, Yanyan ;

Liu, Xingchen ;

Zhang, Qing ;

Zhou, Keshu .

EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)

[80] Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK) [J].

Watterson, Scott H. ;

Liu, Qingjie ;

Bertrand, Myra Beaudoin ;

Batt, Douglas G. ;

Li, Ling ;

Pattoli, Mark A. ;

Skala, Stacey ;

Cheng, Lihong ;

Obermeier, Mary T. ;

Moore, Robin ;

Yang, Zheng ;

Vickery, Rodney ;

Elzinga, Paul A. ;

Discenza, Lorell ;

D'Arienzo, Celia ;

Gillooly, Kathleen M. ;

Taylor, Tracy L. ;

Pulicicchio, Claudine ;

Zhang, Yifan ;

Heimrich, Elizabeth ;

McIntyre, Kim W. ;

Ruan, Qian ;

Westhouse, Richard A. ;

Catlett, Ian M. ;

Zheng, Naiyu ;

Chaudhry, Charu ;

Dai, Jun ;

Galella, Michael A. ;

Tebben, Andrew J. ;

Pokross, Matt ;

Li, Jianqing ;

Zhao, Rulin ;

Smith, Daniel ;

Rampulla, Richard ;

Allentoff, Alban ;

Wallace, Michael A. ;

Mathur, Arvind ;

Salter-Cid, Luisa ;

Macor, John E. ;

Carter, Percy H. ;

Fura, Aberra ;

Burke, James R. ;

Tino, Joseph A. .

JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (07) :3228-3250

← 1 2 3 4 5 6 7 8 9 →